

# Bernhard Eigl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7972672/publications.pdf>

Version: 2024-02-01

136  
papers

7,089  
citations

147801

31  
h-index

58581

82  
g-index

137  
all docs

137  
docs citations

137  
times ranked

8764  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	1.6	1,751
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 67-76.	13.7	1,728
3	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	9.4	376
4	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	10.7	324
5	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. <i>Lancet Oncology</i> , The, 2019, 20, 1730-1739.	10.7	227
6	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4247-4254.	1.6	221
7	Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2766-2774.	7.0	147
8	Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients. <i>European Urology</i> , 2015, 67, 23-29.	1.9	142
9	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. <i>Annals of Oncology</i> , 2016, 27, 454-460.	1.2	142
10	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	7.0	121
11	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. <i>Clinical Cancer Research</i> , 2011, 17, 5765-5773.	7.0	120
12	Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis. <i>Clinical Chemistry</i> , 2005, 51, 1525-1528.	3.2	109
13	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2017, 197, 135-142.	0.4	106
14	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	12.8	85
15	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. <i>Journal of Clinical Oncology</i> , 2019, 37, 3090-3098.	1.6	81
16	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6944-6954.	7.0	71
17	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4905-4911.	7.0	63
18	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. <i>European Urology</i> , 2019, 75, 940-947.	1.9	60

#	ARTICLE	IF	CITATIONS
19	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. <i>Investigational New Drugs</i> , 2015, 33, 969-976.	2.6	50
20	Palliative Radiotherapy Improves Pain and Reduces Functional Interference in Patients with Painful Bone Metastases: A Quality Assurance Study. <i>Clinical Oncology</i> , 2006, 18, 539-544.	1.4	47
21	A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1544-1550.	2.3	45
22	Targeting the Apoptosis Pathway in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 79-89.	2.0	43
23	Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. <i>Canadian Urological Association Journal</i> , 2010, 4, 263-267.	0.6	42
24	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 4610-4623.	7.0	41
25	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>European Urology</i> , 2015, 67, 441-447.	1.9	40
26	Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2009, 33, 233-240.	3.7	39
27	Patterns of Practice in Palliative Radiotherapy for Painful Bone Metastases: Impact of a Regional Rapid Access Clinic on Access to Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 533-538.	0.8	39
28	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
29	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873.	1.8	37
30	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021, 79, 16-19.	1.9	36
31	A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. <i>Annals of Oncology</i> , 2012, 23, 53-58.	1.2	35
32	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 501-508.	1.6	31
33	Cloning and Characterization of cDNA for Adenosine Kinase from Mammalian (Chinese Hamster,) Tj ETQq1 1 0.784314 rgBT /Overloc	0.2	30
34	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 440-446.	1.9	29
35	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 201-208.e1.	1.9	29
36	The impact of time to metastasis on overall survival in patients with prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1039-1046.	2.2	27

#	ARTICLE	IF	CITATIONS
37	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019, 108, 69-77.	2.8	25
38	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatersen and chemotherapy for patients with advanced urothelial cancer. <i>Annals of Oncology</i> , 2017, 28, 2481-2488.	1.2	24
39	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. <i>Journal of Urology</i> , 2019, 202, 49-56.	0.4	24
40	A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5002-5002.	1.6	24
41	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or 3rd) Line Therapy. <i>Urology</i> , 2019, 114, 487.	3.5	23
42	CRAFT: A Proposed Framework for Decentralized Clinical Trials Participation in Canada. <i>Current Oncology</i> , 2021, 28, 3857-3865.	2.2	22
43	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. <i>Cancer Medicine</i> , 2013, 2, 468-477.	2.8	18
44	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018, 4, 733-736.	3.1	18
45	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164.	1.8	18
46	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	1.9	15
47	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. <i>Prostate</i> , 2019, 79, 281-287.	2.3	15
48	A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3014-3014.	1.6	15
49	A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Canadian Urological Association Journal</i> , 2017, 12, E47-52.	0.6	13
50	Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5077-5077.	1.6	13
51	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.6	12
52	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	1.9	12
53	Tolerance of Sunitinib in Dialyzed Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E104-E106.	1.9	11
54	Urinary Large Cell Neuroendocrine Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1399-1408.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. <i>European Journal of Cancer</i> , 2021, 152, 215-222.	2.8	11
56	A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. <i>Journal of Clinical Oncology</i> , 2008, 26, 5166-5166.	1.6	11
57	Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. <i>Npj Genomic Medicine</i> , 2020, 5, 12.	3.8	9
58	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4532-4532.	1.6	9
59	IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2016, 27, vi270.	1.2	8
60	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.6	8
61	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.6	8
62	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , 2021, 26, e1381-e1394.	3.7	8
63	Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5036-5036.	1.6	8
64	Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4549-4549.	1.6	8
65	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583.	0.6	7
66	Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5059-5059.	1.6	7
67	The Future of Systemic Therapies for Localised Prostate Cancer. <i>Clinical Oncology</i> , 2013, 25, 506-513.	1.4	6
68	Evaluation of Prostate-specific Antigen Response Following Cessation of Abiraterone Acetate: Is There Evidence for a Withdrawal Syndrome?. <i>European Urology</i> , 2014, 65, 504-505.	1.9	6
69	Expanding Immunotherapy Options for Bladder Cancer. <i>Urology</i> , 2017, 106, 1-2.	1.0	6
70	A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 143-145.	0.9	6
71	First-line randomized phase II study of gemcitabine/cisplatin plus apatersen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4503-4503.	1.6	5
72	Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5051-5051.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.. Journal of Clinical Oncology, 2018, 36, 569-569.	1.6	5
74	Immunogenomic landscape of neuroendocrine small cell prostate cancer.. Journal of Clinical Oncology, 2019, 37, 217-217.	1.6	5
75	Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal. Journal of Clinical Oncology, 2005, 23, 4617-4617.	1.6	5
76	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational New Drugs, 2016, 34, 771-776.	2.6	4
77	A fountain of knowledge? The quality of online resources for testicular cancer patients. Canadian Urological Association Journal, 2020, 14, E363-E368.	0.6	4
78	A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D).. Journal of Clinical Oncology, 2011, 29, 151-151.	1.6	4
79	Building the Case for Adjuvant Chemotherapy After Radical Cystectomy. Urology, 2016, 94, 1-2.	1.0	3
80	PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI). Journal of Urology, 2016, 195, .	0.4	3
81	Second-Line Systemic Therapies for Metastatic Urothelial Carcinoma: A Population-Based Cohort Analysis. Current Oncology, 2019, 26, 260-265.	2.2	3
82	The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists.. Journal of Clinical Oncology, 2011, 29, 285-285.	1.6	3
83	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).. Journal of Clinical Oncology, 2014, 32, 5078-5078.	1.6	3
84	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology, 2015, 33, 4555-4555.	1.6	3
85	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology, 2017, 35, 4514-4514.	1.6	3
86	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 457-457.	1.6	3
87	Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system?. Canadian Urological Association Journal, 2013, 7, 1-6.	0.6	3
88	Composite chromophobe renal cell carcinoma with sarcomatoid differentiation containing osteosarcoma, chondrosarcoma, squamous metaplasia and associated collecting duct carcinoma: a case report. Analytical and Quantitative Cytopathology and Histopathology, 2014, 36, 235-40.	0.2	3
89	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	12.8	3
90	7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC). European Journal of Cancer, Supplement, 2009, 7, 407.	2.2	2

#	ARTICLE	IF	CITATIONS
91	2535 Clinical outcomes in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis. <i>European Journal of Cancer</i> , 2015, 51, S486-S487.	2.8	2
92	Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. <i>Annals of Oncology</i> , 2016, 27, vi291.	1.2	2
93	Caught in the net: Characterizing how testicular cancer patients use the internet as an information source. <i>Canadian Urological Association Journal</i> , 2021, 15, E400-E404.	0.6	2
94	Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 379-379.	1.6	2
95	A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 113-113.	1.6	2
96	Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).. <i>Journal of Clinical Oncology</i> , 2016, 34, 223-223.	1.6	2
97	Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371. <i>Annals of Oncology</i> , 2017, 28, v325.	1.2	1
98	Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy. <i>Annals of Oncology</i> , 2019, 30, v399.	1.2	1
99	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392.	0.4	1
100	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 29-29.	1.6	1
101	Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 97-97.	1.6	1
102	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5021-5021.	1.6	1
103	Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 260-260.	1.6	1
104	Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16036-e16036.	1.6	1
105	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-526.	1.6	1
106	Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 153-153.	1.6	1
107	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 383-383.	1.6	1
108	Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, e23075-e23075.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 297-297.	1.6	1
110	Assembling a network to promote translational bladder cancer research in Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E475-E481.	0.6	1
111	Utilization of Radiotherapy for Palliation of Bone Metastases: A 3-Year Patterns of Practice Study at a Regional Cancer Centre. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S93-S94.	0.8	0
112	CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY. <i>Journal of Urology</i> , 2009, 181, 229-230.	0.4	0
113	7170 Clinical practice guideline impact on referral and treatment rates of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a comparative analysis between two Canadian tertiary care centres. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 444.	2.2	0
114	Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S361-S362.	0.8	0
115	A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC). <i>Annals of Oncology</i> , 2012, 23, ix304.	1.2	0
116	2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1â,¢ trial of first-line gemcitabine/cisplatin plus apatosen or placebo. <i>European Journal of Cancer</i> , 2015, 51, S525.	2.8	0
117	Localized prostate cancer presenting as a renal pseudo-tumour. <i>Canadian Urological Association Journal</i> , 2015, 9, 505.	0.6	0
118	MP49-01 NEXT GENERATION SEQUENCING OF CELL FREE DNA REVEALS GENOMIC ABERRATIONS IN METASTATIC UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
119	Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer. <i>Annals of Oncology</i> , 2018, 29, viii323-viii324.	1.2	0
120	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 1262-1263.	0.4	0
121	Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2019, 30, v376.	1.2	0
122	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2020, 15, E123-E126.	0.6	0
123	Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 338-338.	1.6	0
124	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 717-717.	0.4	0
125	Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	0
126	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. <i>Urology Case Reports</i> , 2021, 39, 101762.	0.3	0



#	ARTICLE	IF	CITATIONS
127	Cost of care for prostate cancer patients: An observational cohort study comparing clinical trials to standard care.. Journal of Clinical Oncology, 2011, 29, 184-184.	1.6	0
128	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. Journal of Clinical Oncology, 2014, 32, e15616-e15616.	1.6	0
129	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. Journal of Clinical Oncology, 2015, 33, 335-335.	1.6	0
130	Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy.. Journal of Clinical Oncology, 2015, 33, e15633-e15633.	1.6	0
131	Characterizing discontinuation and withdrawal from phase III oncology clinical trials.. Journal of Clinical Oncology, 2015, 33, e17731-e17731.	1.6	0
132	Racial disparities in attrition among oncology clinical trial participants.. Journal of Clinical Oncology, 2015, 33, 6551-6551.	1.6	0
133	Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.. Journal of Clinical Oncology, 2017, 35, 378-378.	1.6	0
134	Abstract 5397: Characterizing the genomic landscape of bladder cancer with circulating tumor DNA. , 2017, , .		0
135	Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).. Journal of Clinical Oncology, 2018, 36, 277-277.	1.6	0
136	A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC).. Journal of Clinical Oncology, 2018, 36, e17026-e17026.	1.6	0